Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Condition(s):MelanomaLast Updated:April 9, 2018Withdrawn
Condition(s):Non-small Cell Lung CancerLast Updated:July 7, 2021Not yet recruiting
Condition(s):MelanomaLast Updated:August 6, 2019Completed
Condition(s):Metastatic Breast CancerLast Updated:April 10, 2023Active, not recruiting
Condition(s):Locally Recurrent or Metastatic Cancer of the Head and Neck; Must Have Failed First-Line TherapyLast Updated:March 14, 2007Completed
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:February 21, 2024Recruiting
Condition(s):Metastatic Gastric CancerLast Updated:December 9, 2020Unknown status
Condition(s):Non Small Cell Lung Cancer; Immune Checkpoint Inhibitor; EGFR Exon 21 MutationLast Updated:November 21, 2023Not yet recruiting
Condition(s):Graft vs Host Disease; Blood and Marrow Transplant (BMT)Last Updated:April 9, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.